Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Maze Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Maze Therapeutics, Inc.’s stock price such as:

• Maze Therapeutics, Inc.’s current stock price and volume
• Why Maze Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for MAZE from analysts
• MAZE’s stock price momentum as measured by its relative strength

About Maze Therapeutics, Inc. (MAZE)

Before we jump into Maze Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Want to learn more about Maze Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Maze Therapeutics, Inc..

Maze Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 12:15 PM, CST, Maze Therapeutics, Inc.’s stock price was $26.630.

Maze Therapeutics, Inc. is down 3.62% from its previous closing price of $27.630.

During the last market session, Maze Therapeutics, Inc.’s stock traded between $25.850 and $27.700. Currently, there are approximately 53.90 million shares outstanding for Maze Therapeutics, Inc..

Maze Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Maze Therapeutics, Inc. Stock Price History

Maze Therapeutics, Inc.’s (MAZE) price is currently down 10.76% so far this month.

During the month of July, Maze Therapeutics, Inc.’s stock price has reached a high of $33.500 and a low of $25.850.

Over the last year, Maze Therapeutics, Inc. has hit prices as high as $53.650 and as low as $12.810. Year to date, Maze Therapeutics, Inc.’s stock is down 35.72%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Maze Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded Maze Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Maze Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Maze Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Maze Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Maze Therapeutics, Inc. (MAZE) by visiting AAII Stock Evaluator.

Relative Price Strength of Maze Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Maze Therapeutics, Inc. has a weighted four-quarter relative price strength of 17.68%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Maze Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Maze Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Maze Therapeutics, Inc.’s stock price is $26.630, which is down 3.62% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Maze Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.